**ZIRP Puerto Rico Study**

**Zika Virus RNA Persistence in Pregnant Women and Congenitally Infected Infants in Puerto Rico (ZIRP)**

**Supporting Statement: Part B**

**OMB # 0920-XXXX**

**September 21, 2017**

**Sascha Ellington, MSPH**

**Telephone: 770-488-6037**

**Fax: 770-488-6391**

**E-mail: frk5@cdc.gov**

**Pregnancy and Birth Defects Task Force**

**CDC Zika Virus Response Team**

**Centers for Disease Control and Prevention**

**Atlanta, Georgia 30341**

**Table of Contents**

|  |
| --- |
| **B. Collections of Information Employing Statistical Methods** |
| 1. Respondent Universe and Sampling Methods |
| 1. Procedures for the Collection of Information |
| 1. Methods to Maximize Response Rates and Deal with Non-response |
| 1. Tests of Procedures or Methods to be Undertaken |
| 1. Individuals Consulted on Statistical Aspects and Individuals Collecting and/or Analyzing Data |

**Attachments**

1. Section 301 of the Public Health Service Act (42 U.S.C. 241)
2. 30-Day Federal Register Notice
3. Screening and Data Collection Instruments
   1. Pregnant Women Screening Form
   2. Pregnant Women Enrollment Questionnaire
   3. Pregnant Women Symptoms Questionnaire
   4. Pregnant Women Follow-up Questionnaire
   5. Infant Enrollment and Delivery Questionnaire
   6. Infant Follow-up Questionnaire
4. Confidentiality and Non-disclosure Agreements
   1. Assurance of Confidentiality Agreement
   2. FTE nondisclosure agreement
   3. Agreement to Abide By Restrictions on Release of Zika Pregnancy and Infant Outcomes Surveillance and Surveillance-Related Data Collected and Maintained by the Centers for Disease Control and Prevention (CDC)
5. IRB Approval
   1. IRB Approval Letter (CDC)
   2. IRB Approval Letter (UPR)
   3. IRB Approval Letter Amendment 1 (CDC)

**ABBREVIATIONS**

CDC Centers for Disease Control and Prevention

EOC Emergency Operations Center

IgM Immunoglobulin M

IRB Institutional Review Board

mL Milliliter

MRI Magnetic Resonance Imagining

OB Obstetric

PRDH Puerto Rico Department of Health

PI Principal Investigator

POC Point of Contact

PRDH Puerto Rico Department of Health

RNA Ribonucleic acid

rRT-PCR Real-time reverse transcription–polymerase chain reaction

USZPR US Zika Pregnancy Registry

ZAPSS Zika Active Pregnancy Surveillance System

ZIKV Zika Virus**B. Collections of Information Employing Statistical Methods**

**B.1. Respondent Universe and Sampling Methods**

The objective of our study is to determine the prevalence and duration of persistent ZIKV RNA in pregnant women infected with ZIKV and their congenitally exposed infants. In order to achieve this, using a hypothetical estimate of the prevalence of ZIKV RNA persistence of 5% after 12 months, and a two-sided 99% confidence interval width of 10% (or margin of error (ME) of ±5%), a sample size of 125 ZIKV positive pregnant women and congenitally-infected infants will be needed. Table B.1.1 shows different scenarios of potential sample sizes that were considered for the study.

**Figure B.1.1. Sample Size calculations for different proportions of pregnant women with prolonged detection of ZIKV RNA within a finite population in Puerto Rico, 2017**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Estimated Proportion of Pregnant Women with Persistent Detection of Zika Virus (ZIKV)RNA** | | | | |
| **Confidence Level (%)** | **3%** | **5%** | **15%** | **30%** | **45%** |
| **95%** | 45 | 73 | 193 | 313 | 367 |
| **80%** | 20 | 32 | 84 | 137 | 161 |
| **90%** | 32 | 52 | 137 | 223 | 261 |
| **97%** | 55 | 89 | 235 | 381 | 446 |
| **99%** | 77 | 125 | 328 | 528 | 617 |
| **99,90%** | 125 | 202 | 524 | 834 | 969 |
| **99,99%** | 174 | 280 | 717 | 1129 | 1304 |

The sample size is tentatively estimated, given that there is little information on prevalence of ZIKV RNA persistence rates available in literature. The final sample size of 150 ZIKV positive pregnant women and their congenitally exposed infants is estimated for evaluation of the primary objectives of the study

**B.2. Procedures for the Collection of Information**

Pregnant women of any gestational age at the time of ZIKV diagnosis and their infants will be invited to participate. The Pregnant Women Screening Form (Att **C**.1) will be administered to potential participants by trained ZIRP research staff, and will be used to confirm participant eligibility prior to consent.

The pregnant woman will consent for her participation. Following consent, information will be collected at baseline regarding demographics and risk factors for ZIKV through the Pregnant Woman Enrollment Questionnaire (Att **C**.2) and a Pregnant Woman Symptom Questionnaire (Att **C**.3). Pregnant women will then be serially tested for ZIKV RNA in blood (7.5mL) and/or urine samples by rRT-PCR and ZIKV Immunoglobulin M (IgM) every two weeks . The blood samples will consist of one venous blood collection (via venipuncture) every two weeks and a one-time collection of capillary blood (via finger prick) at enrollment. If these visits do not coincide with a typical prenatal care visit, they will be asked to come in for a laboratory-only visit to obtain samples and to complete the Pregnant Woman Follow-up questionnaire (Att **C**.4).

Samples will be collected every two weeks until blood and urine samples are all rRT-PCR-negative on two subsequent collection dates to confirm negative results. Once a woman tests rRT-PCR negative on two subsequent collection dates, she will be tested monthly for ZIKV through 1 month post-delivery. All women will continue to have study visits through 3 months post-delivery.

Infants born to women enrolled in the pregnancy cohort will be enrolled when the pregnant woman and the infant’s father sign the infant informed consent form. At birth, the study staff will collect infant information on the Infant enrollment and delivery questionnaire (Att **C**.5), this information will be related to demographics, vital signs, delivery and abnormalities, laboratory sample collection and imaging. Infants will be tested every month after birth until blood and/or urine samples are all rRT-PCR-negative on two subsequent collection dates to confirm negative results. Infants who test rRT-PCR- negative on two subsequent collection dates will continue to have monthly study visits in which only study forms will be completed until six months of age. Infants who are born PCR-negative will have a confirmatory test at month 1 to ensure they continue to be negative and will complete the Infant follow-up questionnaire (Att **C**.6),.

**B.3. Methods to Maximize Response Rates and Deal with Non-response**

Efforts will be made to maximize the response rate. Pregnant women will be encouraged to complete the study throughout the pregnancy up until 3 months post-delivery and their infants up to 6 months of age. To encourage study participation, after being provided with information about the study, potential participants will be given a phone number to call if they have questions about the study. In addition, once a participant is enrolled, study staff will follow-up with participants if a study visit is missed.

There are also a number of ancillary benefits to study participation that are expected to increase participation rates. As a part of this study, participants will have some tests and procedures performed that are not usually available in the standard prenatal care, including serial Zika testing, blood, and urine diagnostic testing. All of these tests and procedures will be paid for by the study as they are not part of the routine clinical care. Participants will also be given any new information gained during the course of the study that might increase their willingness to continue with the study.

Pregnant women and parent(s) may incur extra financial and other costs to participate, as the study will require time for extra clinic and laboratory visits, transportation costs, and the extra time needed to make these visits. To help cover these costs, we plan to offer a $25 gift card for each clinic visit and a $25 gift card for each laboratory visit. Infants will receive a $25 gift card for each clinic visit. These may be given to the participants in the form of cash or transportation tickets to appreciate for their participation.

We anticipate being able to assess non-response bias by examining participation rates. In addition, some information on non-responders may be available from clinics so that we will be able to assess factors associated with non-response.

**B.4. Tests of Procedures or Methods to be Undertaken**

All data collection instruments were reviewed by medical personnel, laboratorians, epidemiologists and subject matter experts for question working and appropriate and adequate response options.

**B.5. Individuals Consulted on Statistical Aspects and Individuals Collecting and/or Analyzing Data**

Data collection instruments were reviewed by medical personnel, laboratorians, epidemiologists and subject matter experts. These included individuals from the CDC Zika Virus Response Team, Pregnancy and Birth Defects Task Force (Margaret Honein, PhD; Sascha Ellington, MSPH; Cristina Valencia, MPH, MSc, EPIET; Abbey Jones, MPH; Carrie Shapiro, PhD, MPH; Dana Meaney-Delman, MD,MPH ), CDC Dengue Branch, Puerto Rico (Jennifer Reed, MD; Jorge Munoz, MD; Janice Perez-Padilla, RN, MPH; Steve Waterman, PhD), University of Puerto Rico (Carmen Zorilla, MD; Alberto de la Vega, MD; Ines Garcia, MD; Juana Rivera, MD) and Puerto Rico Department of Health (Carmen Deseda, MD)

ZIRP Puerto Rico Study designed by:

Pregnancy and Birth Defects Task Force

CDC Zika Virus Response Team

U.S. Centers for Disease Control and Prevention

Centers for Disease Control and Prevention

1600 Clifton Rd., NE

Atlanta, GA 30303

Tel: 770-488-7100

Project Officer: Margaret Honein

E-mail: mrh7@cdc.gov

Puerto Rico Department of Health (PRDH)

Calle Teniente Cesar Luis Gonzalez, 1111

San Juan, Puerto Rico 00927

Tel: (1) 787-765-2929

University of Puerto Rico (UPR)

1187 Calle Flamboyán

San Juan PR 00926-1117

Tel: (1) 787-250-0000

Data collected from 2017-2018 by:

Pregnancy and Birth Defects Task Force

CDC Zika Virus Response Team

U.S. Centers for Disease Control and Prevention

Centers for Disease Control and Prevention

1600 Clifton Rd., NE

Atlanta, GA 30303

Tel: 770-488-7100

Project Officer: Margaret Honein

E-mail: mrh7@cdc.gov

Puerto Rico Department of Health (PRDH)

Calle Teniente Cesar Luis Gonzalez, 1111

San Juan, Puerto Rico 00927

Tel: (1) 787-765-2929

University of Puerto Rico (UPR)

1187 Calle Flamboyán

San Juan PR 00926-1117

Tel: (1) 787-250-0000

Data analyzed by:

Pregnancy and Birth Defects Task Force

CDC Zika Virus Response Team

U.S. Centers for Disease Control and Prevention

Centers for Disease Control and Prevention

1600 Clifton Rd., NE

Atlanta, GA 30303

Tel: 770-488-7100

Project Officer: Margaret Honein

E-mail: [mrh7@cdc.gov](mailto:mrh7@cdc.gov)

Puerto Rico Department of Health (PRDH)

Calle Teniente Cesar Luis Gonzalez, 1111

San Juan, Puerto Rico 00927

Tel: (1) 787-765-2929

University of Puerto Rico (UPR)

1187 Calle Flamboyán

San Juan PR 00926-1117

Tel: (1) 787-250-0000